Background: Evidence to support cryoprecipitate for reversal of alteplase-related hemorrhagic conversion of acute ischemic stroke is limited. Guidelines recommend cryoprecipitate as first line treatment, followed by aminocaproic acid as a conditional recommendation with very low-quality evidence. The purpose of this case series was to describe the use of cryoprecipitate for alteplase-related hemorrhagic conversion of acute ischemic stroke. Methods: This was an IRB-approved retrospective case series of adults who received cryoprecipitate for an alteplase-related hemorrhagic conversion of acute ischemic stroke at two comprehensive stroke centers within a large academic medical center. Thromboembolism at 14 days and hemostasis within 24 hours were collected. The outcomes of cryoprecipitate alone vs cryoprecipitate with aminocaproic acid (C + A) were also described. Results: A total of 19 patients were included. Thrombosis occurred in 1/19 (5%) and hemostasis occurred in 4/14 (29%) of evaluable patients. In-hospital mortality was seen in 9/19 (47%) patients. Seventy four percent (14/19) of patients received concomitant blood products other than cryoprecipitate and 63% received a concomitant reversal agent. Thirteen patients received cryoprecipitate alone and six received C + A. Thrombosis was seen in 1/13 (8%) vs 0/6 (0%) and hemostasis occurred in 2/11 (18%) and 2/3 (67%) evaluable cryoprecipitate vs C + A patients respectively. Conclusion: Cryoprecipitate was associated with a low rate of thrombosis and hemostasis for alteplase-associated hemorrhagic conversion of acute ischemic stroke. There was significant heterogeneity in treatment regimens, including the use of and dosing of adjunctive aminocaproic acid and monitoring of fibrinogen levels.
YaghiSEisenbergerAWilleyJZ. Symptomatic Intracerebral Hemorrhage in Acute Ischemic Stroke After Thrombolysis With Intravenous Recombinant Tissue Plasminogen Activator. JAMA Neurol. 2014;71:1181-1185.
2.
MatratADe MazancourtPDerexL, et al.Characterization of a severe hypofibrinogenemia induced by alteplase in two patients thrombolysed for stroke. Thromb Res. 2013;131:e45-e48.
3.
SpronkESykesGFalcioneS, et al.Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. Front Neurol. 2021;12:661955.
4.
IllohOCIllohK. Thrombolytic-associated coagulopathy and management dilemmas: a review of two cases. Blood Coagul Fibrinolysis. 2008;19:605-607.
5.
GurbelPAHayesKBlidenKPYohoJTantryUS. The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005;16:1-7.
6.
FronteraJALewinJJIIIRabinsteinAA, et al.Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocritical Care. 2016;24:6-46.
7.
PowersWJRabinsteinAAAckersonT, et al.Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50:e344-e418.
8.
YaghiSHaggiagiASherzaiAMarshallRSAgarwalS. Use of recombinant factor VIIa in symptomatic intracerebral hemorrhage following intravenous thrombolysis. Clin Pract (Wash D C). 2015;5:756.
9.
YaghiSBoehmeAKDibuJ, et al.Treatment and Outcome of Thrombolysis-Related Hemorrhage. JAMA Neurol. 2015;72(12):1451-1457.
10.
GoldsteinJNMarreroMMasrurS, et al.Management of Thrombolysis-Associated Symptomatic Intracerebral Hemorrhage. Arch Neurol. 2010;67(8):965-969.
11.
VerkerkBSBergerKLeschCA. Aminocaproic Acid for the Reversal of Alteplase: A Case Series. J Pharm Pract. 2020;33:919-925.
12.
YaghiSWilleyJZCucchiaraB, et al.Treatment and Outcome of Hemorrhagic Transformation After Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2017;48:e343-e361.
13.
WikkelsoAWetterslevJMollerAMAfshariA. Cochrane Emergency and Critical Care Group. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev. 2016;16:CD007871.
14.
MakrisMVan VeenJJTaitCRMumfordADLaffanMBritish Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol. 2013;160:35-46.
15.
EldinKWTeruyaJ. Blood Components for Hemostasis. Lab Med. 2012;43:237-244.
16.
TrouillasPDerexLPhilippeauF, et al.Early Fibrinogen Degradation Coagulopathy Is Predictive of Parenchymal Hematomas in Cerebral rt-PA Thrombolysis. Stroke. 2004;35:1323-1328.
17.
DanésAFCuencaLGBuenoSRMendarte BarrenecheaLRonsanoJBM. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. Vox Sang. 2008;94:221-226.
18.
JuhlRCRoddyJVFWangT-FLiJElefritzJL. Thromboembolic complications following aminocaproic acid use in patients with hematologic malignancies. Leuk Lymphoma. 2018;59:2377-2382.
19.
SinJHBergerKLeschCA. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. J Crit Care. 2016;36:166-172.
20.
BroderickJPBrottTGDuldnerJETomsickTHusterG. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24:987-993.
21.
DavisSMBroderickJHennericiM, et al.Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175-1181.
